Trials / Active Not Recruiting
Active Not RecruitingNCT06566261
ABA-101 in Participants With Progressive Multiple Sclerosis
A Phase 1 Open-label, Single Ascending Dose Study of ABA-101 in Participants With Progressive Multiple Sclerosis
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Abata Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ABA-101 | ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy |
Timeline
- Start date
- 2024-09-11
- Primary completion
- 2026-02-01
- Completion
- 2027-02-01
- First posted
- 2024-08-22
- Last updated
- 2025-07-03
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06566261. Inclusion in this directory is not an endorsement.